Invariant Natural Killer T Cells as a Scalable, Allogeneic Immunotherapy Platform for Inflammation and Cancer
- Demonstrated immune control: iNKT cells act as master regulators of innate and adaptive immunity, reducing pathologic inflammation, promoting tissue repair, and restoring immune homeostasis across inflammatory diseases.
- Clinically validated, allogeneic platform: Off-the-shelf iNKT “living medicines” demonstrate rapid deployability, predictable safety, and scalable manufacturing in immune-dysregulated settings.
- Oncology expansion: With safety, trafficking, and immune modulation established, MiNK is extending iNKT biology into engineered and combination programs— including T-cell engagers (TCEs) and armored FAP-CAR-INKT —to drive deeper efficacy in cancer.